{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:24:53Z","timestamp":1789752293741,"version":"4.0.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.clml.2013.07.011","type":"journal-article","created":{"date-parts":[[2013,11,30]],"date-time":"2013-11-30T15:56:02Z","timestamp":1385826962000},"page":"S307-S309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"S2","title":["Rationale for Targeting the PI3K\/Akt\/mTOR Pathway in Myeloproliferative Neoplasms"],"prefix":"10.1016","volume":"13","author":[{"given":"Niccol\u00f2","family":"Bartalucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2013.07.011_bib1","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJM197406132902419","article-title":"Bone-marrow responses in polycythemia vera","volume":"290","author":"Prchal","year":"1974","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.07.011_bib2","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2006-10-054940","article-title":"The JAK2 V617F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera","volume":"110","author":"Dupont","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.07.011_bib3","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2009-12-259747","article-title":"JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia","volume":"116","author":"Li","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.07.011_bib4","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.07.011_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.exphem.2003.11.003","article-title":"Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera","volume":"32","author":"Ugo","year":"2004","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2013.07.011_bib6","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1124\/pr.110.004051","article-title":"Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory\/autoimmune diseases and hematological malignancies","volume":"64","author":"Foster","year":"2012","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.clml.2013.07.011_bib7","doi-asserted-by":"crossref","first-page":"8204","DOI":"10.1073\/pnas.0502857102","article-title":"The coordinate regulation of the p53 and mTOR pathways in cells","volume":"102","author":"Feng","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2013.07.011_bib8","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1126\/science.1187532","article-title":"mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs","volume":"328","author":"Dowling","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.clml.2013.07.011_bib9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ccr.2010.01.021","article-title":"Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E","volume":"17","author":"Hsieh","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2013.07.011_bib10","doi-asserted-by":"crossref","first-page":"954","DOI":"10.18632\/oncotarget.652","article-title":"Mutations and deregulation of Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR cascades","volume":"3","author":"McCubrey","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2013.07.011_bib11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/1471-2407-8-282","article-title":"TOR complex 2 is needed for cell cycle progression and anchorage-independent growth of MCF7 and PC3 tumor cells","volume":"8","author":"Hietakangas","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2013.07.011_bib12","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ccr.2008.12.017","article-title":"mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice","volume":"15","author":"Guertin","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2013.07.011_bib13","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.4161\/cc.8.8.8206","article-title":"Somatic cell reprogramming control: signaling pathway modulation versus transcription factor activities","volume":"8","author":"Lluis","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.clml.2013.07.011_bib14","first-page":"5371","article-title":"17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes","volume":"60","author":"Wu","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2013.07.011_bib15","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMra0807082","article-title":"Aggressive lymphomas","volume":"362","author":"Lenz","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.07.011_bib16","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2009.03.046","article-title":"DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival","volume":"137","author":"Peterson","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.clml.2013.07.011_bib17","doi-asserted-by":"crossref","first-page":"9643","DOI":"10.1158\/0008-5472.CAN-05-0422","article-title":"Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation","volume":"65","author":"Brandts","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2013.07.011_bib18","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1158\/0008-5472.CAN-04-3888","article-title":"ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors","volume":"65","author":"Kharas","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2013.07.011_bib19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2141.2009.07870.x","article-title":"Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms","volume":"147","author":"Grimwade","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2013.07.011_bib20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2141.2012.09246.x","article-title":"Increased phospho-mTOR expression in megakaryocytic cells derived from CD34+ progenitors of essential thrombocythaemia and myelofibrosis patients","volume":"159","author":"Vicari","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2013.07.011_bib21","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A\u00a0unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.clml.2013.07.011_bib22","doi-asserted-by":"crossref","first-page":"e54826","DOI":"10.1371\/journal.pone.0054826","article-title":"mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms","volume":"8(1)","author":"Bogani","year":"2013","journal-title":"PlosOne"},{"key":"10.1016\/j.clml.2013.07.011_bib23","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1182\/blood.V118.21.3835.3835","article-title":"Inhibitors of PI3K\/Akt and\/or mTOR Inhibit the Growth of Cells of Myeloproliferative Neoplasms and Synergize with JAK2 Inhibitor and Interferon. ASH International Conference","volume":"118","author":"Vannucchi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.07.011_bib24","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2011-01-330563","article-title":"Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1\/2 study in patients with myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501300253X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501300253X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:24:59Z","timestamp":1761870299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226501300253X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":24,"alternative-id":["S215226501300253X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2013.07.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale for Targeting the PI3K\/Akt\/mTOR Pathway in Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2013.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}